Aptabio, Patent for Contrast Agent-Induced Nephropathy Treatment
[Asia Economy Reporter Junho Hwang] Aptabio announced on the 29th that it has obtained a patent related to a treatment for contrast agent-induced acute renal failure.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- Thought to Be Just a Military Force, but Now Controls 40% of Iran’s Economy... IRGC Even Moves Into Cola Business [Company IRGC]①
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
The company stated, "This patent concerns pyrazole derivatives useful for renal protection or the prevention and treatment of contrast agent-induced acute renal failure, their manufacturing methods, and pharmaceutical compositions." It added, "Through this patent, we have confirmed renal protective effects in an acute kidney injury model caused by contrast agents, and plan to utilize this for the development of treatments for contrast agent-induced acute renal failure."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
